Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Martín-Merino E, Fortuny J, Rivero-Ferrer E, Lind M, Garcia Rodriguez LA. Risk factors for diabetic macular oedema in type 2 diabetes: a case-control study in a United Kingdom primary care setting. Prim Care Diabetes. 2017 Jun;11(3):288-96. doi: 10.1016/j.pcd.2017.03.002
Martin-Merino E, Fortuny J, Rivero-Ferrer E, Lind M, Garcia-Rodriguez LA. Risk factors for diabetic retinopathy in people with type 2 diabetes: a case-control study in a UK primary care setting. Prim Care Diabetes. 2016 Aug;10(4):300-8. doi: 10.1016/j.pcd.2016.01.002.
Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients. J Drugs Dermatol. 2015 Feb;14(2):159-66.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Rubino A, Rousculp MD, Davis KL, Wang J, Girach A. Diagnosed diabetic retinopathy in France, Italy, Spain, and the United Kingdom. Prim Care Diabetes. 2007 Jun;1(2):75-80.
Mansfield CA, Pattanayak SK, McDow W, MacDonald R, Halpin P. Shades of green: measuring the value of urban forests in the housing market. J Forest Econ. 2005 Dec;11(3):177-99. doi: 10.1016/j.jfe.2005.08.002